Reproducing human and cross-species drug toxicities using a Liver-Chip
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Nonclinical rodent and nonrodent toxicity models used to support clinical trials of candidate drugs may produce discordant results or fail to predict complications in humans, contributing to drug failures in the clinic. Here, we applied microengineered Organs-on-Chips technology to design a rat, dog, and human Liver-Chip containing species-specific primary hepatocytes interfaced with liver sinusoidal endothelial cells, with or without Kupffer cells and hepatic stellate cells, cultured under physiological fluid flow. The Liver-Chip detected diverse phenotypes of liver toxicity, including hepatocellular injury, steatosis, cholestasis, and fibrosis, and species-specific toxicities when treated with tool compounds. A multispecies Liver-Chip may provide a useful platform for prediction of liver toxicity and inform human relevance of liver toxicities detected in animal studies to better determine safety and human risk.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the current available in vivo and in vitro DILI models have low and inadequate predictive capability.7,8”
From A High-Throughput Microphysiological Liver Chip System to Model Drug-Induced Liver Injury Using Human Liver Organoids (2024) · cites this paper as [8]
In the citing paper
“Albumin and urea production are widely accepted as functional markers for cultured hepatocytes with the goal of reaching computed production levels observed in human liver in vivo (~20–105 µg and 56–159 µg per 106 hepatocytes per day, respectively)19,26.”
From Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (2022) · cites this paper as [26]
In the citing paper
“as well as superior activity relative to hepatocytes in a 2D sandwich-assay plate configuration26.”
From Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (2022) · cites this paper as [26]
In the citing paper
“previously, the same Liver-Chip has been shown to exhibit Phase I and II functional activities that are comparable to freshly isolated human hepatocytes and 3D hepatic spheroids26,30”
From Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (2022) · cites this paper as [26]
Citations
Cites
Reconstituting organ-level lung functions on a chip
Huh, D., Matthews, B. D., Mammoto, A., Montoya-Zavala, M., Hsin, H. Y., & Ingber, D. E. (2010) · Science · doi:10.1126/science.1188302 · Cited by 4,250
Self-citationBhatia, S. N., & Ingber, D. E. (2014) · Nature Biotechnology · doi:10.1038/nbt.2989 · Cited by 3,305
Self-citationConcordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050 · cited 1×
“An analysis of 150 drugs that caused adverse events in humans found that regulatory testing in rats and dogs correctly predicted just 71% of toxicities in humans (1).”
BackgroundFrom 3D cell culture to organs-on-chips
Huh, D., Hamilton, G. A., & Ingber, D. E. (2011) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.09.005 · Cited by 1,834 · cited 1×
“In addition, dense 3D constructs often suffer from limited oxygen and nutrient transport, and even when spheroid cultures include endothelial cells and Kupffer cells, they lack physiologically relevant tissue-tissue interfaces and cytoarchitecture that has been demonstrated to be a key driver of cell function (10, 42).”
BackgroundSelf-citationOrgans-on-chips at the frontiers of drug discovery
Esch, E. W., Bahinski, A., & Huh, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4539 · Cited by 1,185
Mechanisms of Acetaminophen-Induced Liver Necrosis
Hinson, J. A., Roberts, D. W., & James, L. P. (2010) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-00663-0_12 · Cited by 1,006 · cited 1×
“APAP toxicity is caused by direct injury to hepatocytes mediated by the toxic and reactive metabolite N-acetyl-p-benzoquinone imine that depletes cellular glutathione (GSH), causing oxidative stress; it can also be detoxified by hepatocytes, resulting in formation of glucuronide and sulfate metabolites (27).”
BackgroundBjörnsson, E. S., Bergmann, O. M., Björnsson, H. K., Kvaran, R. B., & Olafsson, S. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.006 · Cited by 865
Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment
Jang, K.-J., Mehr, A. P., Hamilton, G. A., McPartlin, L. A., Chung, S., Suh, K.-Y., & Ingber, D. E. (2013) · Integrative Biology · doi:10.1039/c3ib40049b · Cited by 849
Self-citationMcGill, M. R., Sharpe, M. R., Williams, C. D., Taha, M., Curry, S. C., & Jaeschke, H. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59755 · Cited by 763 · cited 1×
“Mitochondrial dysfunction has been identified as a hazard for APAP toxicity (47).”
BackgroundDevelopment of a primary human Small Intestine-on-a-Chip using biopsy-derived organoids
Kasendra, M., Tovaglieri, A., Sontheimer-Phelps, A., Jalili-Firoozinezhad, S., Bein, A., Chalkiadaki, A., Scholl, W., Zhang, C., Rickner, H., Richmond, C. A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-21201-7 · Cited by 754
Self-citationBell, C. C., Hendriks, D. F. G., Moro, S. M. L., Ellis, E., Walsh, J., Renblom, A., Fredriksson Puigvert, L., Dankers, A. C. A., Jacobs, F., Snoeys, J., et al. (2016) · Scientific Reports · doi:10.1038/srep25187 · Cited by 739
Microengineered physiological biomimicry: Organs-on-Chips
Huh, D., Torisawa, Y.-S., Hamilton, G. A., Kim, H. J., & Ingber, D. E. (2012) · Lab on a Chip · doi:10.1039/c2lc40089h · Cited by 667
Self-citationOrgans-on-a-Chip: A Fast Track for Engineered Human Tissues in Drug Development
Ronaldson-Bouchard, K., & Vunjak-Novakovic, G. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.02.011 · Cited by 657
Du, K., Ramachandran, A., & Jaeschke, H. (2016) · Redox Biology · doi:10.1016/j.redox.2016.10.001 · Cited by 569 · cited 1×
“Together, this confirms the reported role of ROS in APAP-induced hepatotoxicity (28).”
BackgroundIn vitro models for liver toxicity testing
Soldatow, V. Y., LeCluyse, E. L., Griffith, L. G., & Rusyn, I. (2013) · Toxicol. Res. · doi:10.1039/c2tx20051a · Cited by 472
Drug-induced liver injury: recent advances in diagnosis and risk assessment
Kullak-Ublick, G. A., Andrade, R. J., Merz, M., End, P., Benesic, A., Gerbes, A. L., & Aithal, G. P. (2017) · Gut · doi:10.1136/gutjnl-2016-313369 · Cited by 438
Mechanisms of action of methotrexate
Genestier, L., Paillot, R., Quemeneur, L., Izeradjene, K., & Revillard, J.-P. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)00189-2 · Cited by 424
Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR
Tolson, A. H., & Wang, H. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.08.006 · Cited by 386 · cited 1×
“These three isoforms also represent the major CYPs regulated by the xenosensors aryl hydrocarbon receptor, constitutive androstane receptor, and pregnane X receptor (20).”
BackgroundSwift*, B., Pfeifer*, N. D., & Brouwer, K. L. R. (2010) · Drug Metabolism Reviews · doi:10.3109/03602530903491881 · Cited by 365 · cited 1×
“It has been reported that sandwich culture can also form extensive canalicular networks, but these are not sustained over 14 days and generally persist up to 7 days in culture (15, 16).”
BackgroundUtility of spherical human liver microtissues for prediction of clinical drug-induced liver injury
Proctor, W. R., Foster, A. J., Vogt, J., Summers, C., Middleton, B., Pilling, M. A., Shienson, D., Kijanska, M., Ströbel, S., Kelm, J. M., et al. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-2002-1 · Cited by 328 · cited 1×
“In other complex cell-based liver models including 3D human spheroid hepatic cultures, the IC50 was found to be more than 10-fold higher than in vivo (25).”
BackgroundSelf-citationIdiosyncratic Drug Reactions: Past, Present, and Future
Uetrecht, J. (2008) · Chemical Research in Toxicology · doi:10.1021/tx700186p · Cited by 257
Drug-induced Acute Liver Failure
Lee, W. M. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2013.07.001 · Cited by 257
Mimicking liver sinusoidal structures and functions using a 3D-configured microfluidic chip
Du, Y., Li, N., Yang, H., Luo, C., Gong, Y., Tong, C., Gao, Y., Lü, S., & Long, M. (2017) · Lab on a Chip · doi:10.1039/c6lc01374k · Cited by 241
A human liver microphysiology platform for investigating physiology, drug safety, and disease models
Vernetti, L. A., Senutovitch, N., Boltz, R., DeBiasio, R., Ying Shun, T., Gough, A., & Taylor, D. L. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370215592121 · Cited by 226 · cited 1×
“Although DILI responses to various drugs were measured in other MPS liver models (41, 44, 46), the drug concentrations used were not clinically relevant.”
BackgroundFontana, R. J., Hayashi, P. H., Gu, J., Reddy, K. R., Barnhart, H., Watkins, P. B., Serrano, J., Lee, W. M., Chalasani, N., Stolz, A., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.03.045 · Cited by 218
Coon, J., Hamilton, G., Jolley, S., Gilbert, D., Barros, S., & LeCluyse, E. (2001) · Cell and Tissue Research · doi:10.1007/s004410100429 · Cited by 193
Self-citationMonticello, T. M., Jones, T. W., Dambach, D. M., Potter, D. M., Bolt, M. W., Liu, M., Keller, D. A., Hart, T. K., & Kadambi, V. J. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.09.006 · Cited by 186 · cited 1×
“This was further confirmed by a more recent survey comparing target organ toxicities in animal and first-inhuman studies that also found a low concordance of DILI between human and animals (2).”
ResultBioengineered Liver Models for Drug Testing and Cell Differentiation Studies
Underhill, G. H., & Khetani, S. R. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.11.012 · Cited by 171 · cited 1×
“Although DILI responses to various drugs were measured in other MPS liver models (41, 44, 46), the drug concentrations used were not clinically relevant.”
BackgroundIn vitro platforms for evaluating liver toxicity
Bale, S. S., Vernetti, L., Senutovitch, N., Jindal, R., Hegde, M., Gough, A., McCarty, W. J., Bakan, A., Bhushan, A., Shun, T. Y., et al. (2014) · Experimental Biology and Medicine · doi:10.1177/1535370214531872 · Cited by 155
Cho, T., & Uetrecht, J. (2017) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00357 · Cited by 150 · cited 2×
“This exemplifies the advantage of the Liver-Chip for assessing the pathophysiological consequence of reactive metabolite formation, which has been strongly associated with idiosyncratic DILI (37, 54, 55).”
BackgroundKaku, K., Enya, K., Nakaya, R., Ohira, T., & Matsuno, R. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12467 · Cited by 148
Radi, Z. A., Koza‐Taylor, P., Bell, R. R., Obert, L., Runnels, H. A., BEEBE, J. S., Lawton, M. P., & Sadis, S. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.03.029 · Cited by 145 · cited 2×
“S6A) in a human phase 1 clinical trial that was attributed to mechanism-based Kupffer cell depletion, which can play a role in the clearance of transaminases (29).”
BackgroundLeslie, E. M., Watkins, P. B., Kim, R. B., & Brouwer, K. L. R. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.119073 · Cited by 137 · cited 2×
“Inhibition of the bile salt export pump (BSEP), resulting in hepatocellular accumulation of bile salts, is the putative mechanism for bosentan-mediated DILI (21, 22).”
BackgroundLi, X., George, S. M., Vernetti, L., Gough, A. H., & Taylor, D. L. (2018) · Lab on a Chip · doi:10.1039/c8lc00418h · Cited by 137
Rantakari, P., Patten, D. A., Valtonen, J., Karikoski, M., Gerke, H., Dawes, H., Laurila, J., Ohlmeier, S., Elima, K., Hübscher, S. G., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1604780113 · Cited by 119
Lee, E.-W., Lai, Y., Zhang, H., & Unadkat, J. D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513825200 · Cited by 109 · cited 2×
“The species-specific expression of nucleoside transporters in the mitochondria of humans, but not of other animals, can explain why the preclinical toxicology testing of FIAU in mice, rats, dogs, and primates failed to predict humanspecific mitochondrial toxicity and hepatotoxicity of FIAU to humans (32, 49).”
BackgroundSpaggiari, D., Geiser, L., Daali, Y., & Rudaz, S. (2014) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2014.03.018 · Cited by 100 · cited 1×
“We used prototypical probe substrates in a cocktail approach using concentrations of their respective substrates (phenacetin, bupropion, and midazolam) or a single substrate (cyclophosphamide for CYP2B and testosterone for CYP3A in the human model) that mirror their Michaelis constant (Km) in humans (19).”
MethodExploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury
Woodhead, J. L., Yang, K., Siler, S. Q., Watkins, P. B., Brouwer, K. L. R., Barton, H. A., & Howell, B. A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00240 · Cited by 93 · cited 1×
“Inhibition of the bile salt export pump (BSEP), resulting in hepatocellular accumulation of bile salts, is the putative mechanism for bosentan-mediated DILI (21, 22).”
BackgroundOtieno, M. A., Snoeys, J., Lam, W. W., Ghosh, A., Player, M. R., Pocai, A., Salter, R., Simic, D., Skaggs, H. S., Singh, B., et al. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx040 · Cited by 89 · cited 1×
“In vitro and in vivo studies identified formation of reactive acyl glucuronide metabolites, suppression of mitochondrial respiration, and inhibition of hepatic transporters by TAK-875 as potential mediators of its hepatotoxic effects (35).”
BackgroundSelf-citationLeifke, E., Naik, H., Wu, J., Viswanathan, P., DeManno, D., Kipnes, M., & Vakilynejad, M. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.43 · Cited by 88
Xu, D., Nishimura, T., Nishimura, S., Zhang, H., Zheng, M., Guo, Y.-Y., Masek, M., Michie, S. A., Glenn, J., & Peltz, G. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001628 · Cited by 86 · cited 1×
“4, A and B), which is consistent with previous nonclinical data (32) and studies in humanized hepatocyte mouse models that demonstrate species differences in steatosis compared to wild-type mice (33).”
ResultEpidemiology and Risk Factors for Idiosyncratic Drug-Induced Liver Injury
Björnsson, E. (2014) · Seminars in Liver Disease · doi:10.1055/s-0034-1375953 · Cited by 79 · cited 1×
“This exemplifies the advantage of the Liver-Chip for assessing the pathophysiological consequence of reactive metabolite formation, which has been strongly associated with idiosyncratic DILI (37, 54, 55).”
BackgroundChang, S.-Y., Voellinger, J. L., Van Ness, K. P., Chapron, B., Shaffer, R. M., Neumann, T., White, C. C., Kavanagh, T. J., Kelly, E. J., & Eaton, D. L. (2017) · Toxicology in Vitro · doi:10.1016/j.tiv.2017.01.007 · Cited by 49 · cited 1×
“The quantitative range of albumin production we measured in the human Liver-Chip between days 7 and 14 (~20 to 70 g day−1 per million cells) was very similar to that estimated for humans in vivo (50 g day−1 per million cells) using in vitro–to–in vivo extrapolation (iViVE) techniques (18).”
MethodMARCINAK, J. F., Munsaka, M., Watkins, P. B., Ohira, T., & Smith, N. N. (2018) · Drug Safety · doi:10.1007/s40264-018-0642-6 · Cited by 49 · cited 2×
“For instance, putative adverse pathways for TAK-875–mediated DILI were detected in discrete in vitro models (34); however, the physiological consequence of perturbing these mechanisms could not be studied.”
BackgroundAxworthy, D. B., Hoffmann, K., Streeter, A. J., Calleman, C. J., Pascoe, G. A., & Baillie, T. A. (1988) · Chemico-Biological Interactions · doi:10.1016/0009-2797(88)90009-9 · Cited by 48 · cited 1×
“This is supported by studies in mice in which APAP metabolites were detected bound to reticulocytes, which lack drug-metabolizing enzymes, indicating that these metabolites also escape hepatocytes in vivo (48).”
ResultSelf-citationBarber, J. A., Stahl, S. H., Summers, C., Barrett, G., Park, B. K., Foster, J. R., & Kenna, J. G. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv159 · Cited by 39 · cited 1×
“It has been reported that sandwich culture can also form extensive canalicular networks, but these are not sustained over 14 days and generally persist up to 7 days in culture (15, 16).”
BackgroundYamamoto, T., Kaizu, C., Kawasaki, T., Hasegawa, G., Umezu, H., Ohashi, R., Sakurada, J., Jiang, S. S., Shultz, L. D., & Naito, M. (2008) · Cell and Tissue Research · doi:10.1007/s00441-008-0586-8 · Cited by 36 · cited 1×
“Studies in genetically altered mice previously found the CSF-1/CSFR pathway to be essential for survival of Kupffer cells (50).”
BackgroundFahrmayr, C., König, J., Auge, D., Mieth, M., Münch, K., Segrestaa, J., Pfeifer, T., Treiber, A., & Fromm, M. F. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12126 · Cited by 28 · cited 2×
“The putative mechanism for bosentan-induced liver toxicity—inhibition of bile acid efflux via BSEP resulting in intracellular accumulation of bile acids and inhibition of MRP2 that could be secondary to formation of bosentan glucuronide (26)—was also confirmed; an advantage of the Liver-Chip is that we could couple th…”
BackgroundMasek-Hammerman, K., Peeva, E., Ahmad, A. M., Menon, S. S., Afsharvand, M., Qu, R. P., Cheng, J. B., Syed, J., Zhan, Y., O'Neil, S. P., et al. (2015) · Clinical & Experimental Immunology · doi:10.1111/cei.12705 · Cited by 28 · cited 1×
“Transaminase elevations have been observed with other agents that inhibit CSF-1/CSF-1R (51).”
BackgroundWang, Y., Yu, W., Shen, C., Wang, W., Zhang, L. R., Liu, F., Sun, H., Zhao, Y., Che, H., & Zhao, C. (2017) · Scientific Reports · doi:10.1038/srep40404 · Cited by 27 · cited 1×
“As we observed the release of cytokines/chemokines including IP10 in chips treated with MTX, FIAU, and JNJ-2, which has been identified as a potential marker for fibrosis (52), this model may also be amenable to biomarker discovery, especially for challenging disease areas such as steatosis and fibrosis for which suit…”
BackgroundCXC chemokine IP-10: a key actor in liver disease?
Chen, L., Lv, J., Wen, X., & Niu, J. (2013) · Hepatology International · doi:10.1007/s12072-013-9445-0 · Cited by 26 · cited 1×
“These changes were also associated with increases in interferon-– induced protein 10 kDa (IP-10), a chemokine whose elevation is associated with liver inflammation and fibrosis (31).”
BackgroundGutierrez, M. M., Nicolas, L. B., Donazzolo, Y., & Dingemanse, J. (2013) · Int. Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp201806 · Cited by 15 · cited 1×
“4 M) that has been associated with DILI in humans (23).”
Background
Research works printed but not linked: 3
- Food and Drug Administration Drug Approval Package : Tracleer (Bosentan) (Food and Drug Administration 2001) pp. 21–290.
- Institute of Medicine (U.S) Committee to Review the Fialuridine (FIAU/FIAC) Clinical Trials in Review of the Fialuridine (FIAU) Clinical Trials F. J. Manning M. N. Swartz Eds. (National Academy Press 1995) 269 pp.
- Food and Drug Administration The Food and Drug Administration Predictive Toxicology Roadmap and Its Implementation; Public Hearing; Request for Comments (Office of the Federal Register National Archives and Records Administration 2018) vol. 83 pp. 30595–30598.
Cited by
Human organs-on-chips for disease modelling, drug development and personalized medicine
Ingber, D. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-022-00466-9 · Cited by 1,589
Self-citationA guide to the organ-on-a-chip
Leung, C. M., de Haan, P., Ronaldson-Bouchard, K., Kim, G.-A., Ko, J., Rho, H. S., Chen, Z., Habibovic, P., Jeon, N. L., Takayama, S., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00118-6 · Cited by 1,116
Organs-on-chips: into the next decade
Low, L. A., Mummery, C., Berridge, B. R., Austin, C. P., & Tagle, D. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0079-3 · Cited by 1,029
Limitations of Animal Studies for Predicting Toxicity in Clinical Trials
Van Norman, G. A. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.10.008 · Cited by 732
Organ-on-a-Chip: A New Paradigm for Drug Development
Ma, C., Peng, Y., Li, H., & Chen, W. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.11.009 · Cited by 576
“Many drugs may show no adverse effects on animals during the preclinical stage but unpredictably exhibit hepatic, cardiac, or renal impairments in patients during clinical trials [3, 4].”
Background
Metadata
- Authors
- Jang, K.-J., Otieno, M. A., Ronxhi, J., Lim, H.-K., Ewart, L., Kodella, K. R., Petropolis, D. B., Kulkarni, G., Rubins, J. E., Conegliano, D., Nawroth, J., Simic, D., Lam, W., Singer, M., Barale, E., Singh, B., Sonee, M., Streeter, A. J., Manthey, C., Jones, B., Srivastava, A., Andersson, L. C., Williams, D., Park, H., Barrile, R., Sliz, J., Herland, A., Haney, S., Karalis, K., Ingber, D. E., & Hamilton, G. A.
- Affiliations
- Emulate (United States) (US)
- Janssen Pharmaceutical Research and Development, Nonclinical Safety, 1400 Welsh and McKean Road, Spring House, PA 19477, USA.
- Janssen Pharmaceutical Research and Development, Drug Metabolism and Pharmacokinetics, 1400 Welsh and McKean Road, Spring House, PA 19477, USA.
- AstraZeneca (United Kingdom) (GB)
- Emulate Inc., 27 Drydock Avenue, Boston, MA 02210, USA.
- Janssen Pharmaceutical Research and Development, IPD Biology, 1400 Welsh and McKean Road, Spring House, PA 19477, USA.
- AstraZeneca (Sweden) (SE)
- Harvard University (US)
- Boston Children's Hospital (US)
- Corresponding author
- Otieno, Monicah A.
- Hamilton, Geraldine A.
- ORCID
- Jang, Kyung-Jin
- Otieno, Monicah A.
- Ronxhi, Janey
- Lim, Heng-Keang
- Ewart, Lorna
- Kodella, Konstantia R.
- Petropolis, Debora B.
- Kulkarni, Gauri
- Rubins, Jonathan E.
- Conegliano, David
- Nawroth, Janna
- Lam, Wing
- Singer, Monica
- Barale, Erio
- Singh, Bhanu
- Sonee, Manisha
- Streeter, Anthony J.
- Manthey, Carl
- Srivastava, Abhishek
- Andersson, Linda C.
- Williams, Dominic
- Park, Hyoungshin
- Barrile, Riccardo
- Sliz, Josiah
- Herland, Anna
- Karalis, Katia
- Ingber, Donald E.
- Hamilton, Geraldine A.
- Venue
- Science Translational Medicine
- Published
- 2019-11-06
- Volume
- 11
- Issue
- 517
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2983383732
- Cited by
- 511
- References
- 52
- Citations by year
- 2026: 87 · 2025: 73 · 2024: 66 · 2023: 71 · 2022: 79 · 2021: 83 · 2020: 47 · 2019: 5
- FWCI
- 53.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Janssen Biotech
- Janssen Pharmaceuticals
- the Defense Advanced Research Projects Agency (W911NF-12-2-0036)
- the Wyss Institute for Biologically Inspired Engineering at Harvard University
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Keywords
- organ-on-a-chip, drug toxicity prediction, hepatotoxicity, species-specific toxicity, primary hepatocytes, liver sinusoidal endothelial cells, Kupffer cells, hepatic stellate cells, hepatocyte injury, steatosis, cholestasis, liver fibrosis, microfluidic organ models
- MeSH terms
- Animals, Dogs, Humans, Kupffer Cells, Liver, Liver Diseases, Phenotype, Risk Factors, Species Specificity, Reproducibility of Results, Biomarkers, Rats, Chemical and Drug Induced Liver Injury, Lab-On-A-Chip Devices, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.